Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02567799 · ClinicalTrials.gov registry record · Phase 1
BIO 300 Non-Small Cell Lung Cancer Study
A Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Humanetics Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 4
- Study locations
NCT02567799 is a Phase 1 study of Carcinoma, Non-Small Cell Lung that has completed, run by Humanetics Corporation. The registered enrollment target is 21 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT02567799, a Phase 1 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Humanetics Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine the safety and effectiveness of BIO 300 Oral Suspension when used in combination with standard dose radiation therapy and chemotherapy in patients with non-small cell lung cancer. Based on preclinical data the investigators hypothesize that BIO 300 Oral Suspension will reduce the incidence of radiation-induced pneumonitis and pulmonary fibrosis.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- RADIATION Radiotherapy
- DRUG BIO 300 Oral Suspension
Study Locations (4)
Wisconsin
- Medical College of Wisconsin - Milwaukee
- Zablocki VA Medical Center - Milwaukee
Maryland
- University of Maryland School of Medicine - Baltimore
Michigan
- Henry Ford Hospital - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-11 |
| Est. Completion | 2020-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02567799
The ClinicalTrials.gov registry entry for NCT02567799 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (94% lower). The listed sponsor is Humanetics Corporation, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT02567799 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Wisconsin, Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT02567799 about?
NCT02567799 is a clinical study titled "BIO 300 Non-Small Cell Lung Cancer Study". The purpose of this study is to determine the safety and effectiveness of BIO 300 Oral Suspension when used in combination with standard dose radiation therapy and chemotherapy in patients with non-small cell lung cancer. Based on preclinical data the investigators hypothesize that BIO 300 Oral Susp...
What is the current status of trial NCT02567799?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2015-11. Estimated completion is 2020-09.
What conditions does trial NCT02567799 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT02567799?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Radiotherapy (RADIATION), BIO 300 Oral Suspension (DRUG).
Who is sponsoring clinical trial NCT02567799?
This trial is sponsored by Humanetics Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02567799 being conducted?
This trial has 4 study locations across Maryland, Michigan, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.